证券代码：600196 证券简称：复星医药 公告编号：临2026-030 上海复星医药（集团）股份有限公司2026年第一次临时股东会、2026年第一次A股类别股东会 及2026年第一次H股类别股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议有无否决议案：有，2026年第一次A股类别股东会议案1（即关于分拆所属子公司复星安特 金至香港联交所主板上市仅向本公司H股股东提供保证配额的议案）未获得出席该类别股东会的有表决 权中小股东所持表决权的三分之二以上审议通过。据此，本次分拆上市不会向本公司任何A股或H股股 东提供保证配额。 特别说明：该议案被否决不会影响本公司分拆所属子公司复星安特金于香港联交所主板上市方案的实 施。 一、会议召开和出席情况 （一）股东会召开的日期：2026年2月27日 （二）股东会召开的地点：上海市虹许路358号上海天禧嘉福璞缇酒店 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 注：截至本次会议之股权登记日（即A股股权登记日为2026年2月 ...

截至2026年2月27日收盘，复星医药（600196）报收于26.48元，较前一交易日下跌0.11%，最新总市值 为707.13亿元。该股当日开盘26.51元，最高26.6元，最低26.42元，成交额达3.34亿元，换手率为0.6%。 最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《复星医药：上海市方达律师事务所关于上海复星医药（集团）股份有限公司分拆复星安特金 （成都）生物制药股份有限公司至香港联合交易所有限公司主板上市相关内幕信息知情人买卖股 票情况自查报告的专项核查意见》 《复星医药关于向专业投资者公开发行科技创新公司债券获中国证监会注册批复的公告》 《复星医药：中国国际金融股份有限公司关于上海复星医药（集团）股份有限公司分拆所属子公 司复星安特金（成都）生物制药股份有限公司至香港联合交易所有限公司主板上市相关内幕信息 知情人买卖公司股票情况专项核查意见》 《复星医药关于分拆所属子公司至香港联合交易所有限公司主板上市相关内幕信息知情人买卖本 公司股票情况的自查报告》 近日，上海复星医药（集团）股份有限公司收到中 ...

从联合利华分拆独立上市后，梦龙冰淇淋公司的首份财报遭遇"滑铁卢"。近日，梦龙冰淇淋公司再次重 申2026年战略重点，包括聚焦低糖、植物基产品创新，强化中国市场的本地化投入，并考虑收购中国或 欧美特色品牌以拓展业务版图。此前，梦龙冰淇淋公司披露的2025年财报显示，其全年营收为79亿欧 元，与上年基本持平，但净利润3.07亿欧元较2024年的5.95亿欧元锐减48.4%，几近腰斩。冰淇淋市场 具有韧性，梦龙仍在中国市场实现了有机销售额高个位数增长，市场份额稳居第二。不过，梦龙要想在 2026年实现此前管理层提出的5%增长，仍有不小难度。 业绩骤降 在这份财报中，颇受瞩目的是，梦龙冰淇淋自2025年12月独立上市后，首份财报净利润同比锐减48.4% 至3.07亿欧元。财报显示，净利润下滑的主要原因，包括分拆及重组成本增加1.18亿欧元、净财务成本 增加1.04亿欧元以及汇率波动对经营业绩的影响。 对于中国市场，梦龙冰淇淋公司依然非常有信心。今年初，梦龙冰淇淋公司计划在中国市场推出近30款 新品，覆盖旗下梦龙、可爱多、和路雪及千层雪等品牌。这也是其在2025年12月完成独立上市后，首次 以全新企业形象对中国市场进行 ...

Core Viewpoint - Yanzhou Coal Mining Company Limited (兖矿能源) announced the proposed spin-off of its subsidiary, Kason Technology Co., Ltd. (卡松科技), to be listed on the National Equities Exchange and Quotations (新三板) [1] Group 1 - The company has submitted an application for the proposed spin-off to the Hong Kong Stock Exchange (香港联交所) [1] - The board of directors has received approval from the Hong Kong Stock Exchange under the Listing Rules, specifically the "Application Guidance No. 15" [1] - The company has obtained a letter of consent from the National Equities Exchange and Quotations Co., Ltd. (全国中小企业股份转让系统有限责任公司) for the public transfer and listing of Kason Technology's shares [1]

Core Viewpoint - The company, Sihuan Pharmaceutical (00460), has announced a positive earnings forecast, expecting revenue of at least 2.5 billion RMB for the year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1][5]. Group 1: Financial Performance - The company anticipates a net profit of no less than 150 million RMB for the same period [1][5]. - The growth in performance is primarily driven by the rapid expansion of the medical aesthetics business, which is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1][5]. Group 2: Business Segments - The medical aesthetics segment has become the largest contributor to both revenue and profit for the company, significantly boosting overall performance [1][5]. - The innovative drug business is entering a harvest phase, which is expected to improve the company's profit structure [1][5]. Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves, having conducted multiple rounds of share buybacks and completed the spin-off of Xuan Bamboo Biotechnology, which has optimized the financial structure and driven profit breakthroughs [1][5].

Core Viewpoint - Four Seasons Pharmaceutical (00460) anticipates significant revenue growth, projecting at least 2.5 billion RMB in revenue and 150 million RMB in net profit for the fiscal year ending December 31, 2025, driven primarily by its aesthetic medicine business and innovative drug segment [1] Group 1: Financial Performance - The company expects revenue growth of over 30% compared to the same period last year, with a minimum revenue target of 2.5 billion RMB [1] - Net profit is projected to be no less than 150 million RMB for the same period [1] Group 2: Business Segments - The aesthetic medicine segment is expected to generate over 1.4 billion RMB in revenue and over 700 million RMB in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, significantly improving the company's profit structure [1] Group 3: Financial Health - The company maintains a robust financial position with ample cash reserves [1] - Multiple rounds of share buybacks have been implemented, and the successful spin-off of Xuan Bamboo Biotechnology has optimized the company's financial structure, contributing to profit breakthroughs [1]

Spin-off and Listing - Weisheng Group (03393.HK) plans to spin off Weisheng Information Technology for independent listing on the Sci-Tech Innovation Board [1] Resumption and Suspension - Huaneng International (01102.HK) terminates previous subscription agreement and plans to issue 1.8 billion shares at a 19% discount to Shuncheng International, resuming trading on April 8 [1] Earnings Forecast - Zoomlion Heavy Industry (01157.HK) expects a net profit increase of 125.61%-178.69% to between 850 million and 1.05 billion yuan for the first quarter [1] - VTech Holdings (00303.HK) anticipates a 15%-20% decline in net profit for the fiscal year 2019 due to lower-than-expected sales of telecommunications products in the second half [1] - Changhong Jiahua (08016.HK) forecasts a net profit increase of over 50% for the first quarter [1] - MINDTELL TECH (08611.HK) expects a 51.7% decline in profit for the first quarter [1] Operational Data - China Overseas Development (00688.HK) reports first-quarter sales of 79.536 billion HKD, a year-on-year increase of 21% [1] - Agile Group (03383.HK) records a first-quarter pre-sale amount of 25.08 billion yuan, up 18.4% year-on-year [1] - Greentown China (03900.HK) sees total contract sales drop by 8.6% to 25.5 billion yuan from January to March [1] - Longfor Properties (03380.HK) reports a 7% increase in contract sales to 17.01 billion yuan for the first quarter [1] - Times China Holdings (01233.HK) achieves contract sales of 13.97 billion yuan in the first quarter [1] - First Creation Properties (02868.HK) records a signing amount of 13.91 billion yuan, a year-on-year increase of 63.2% [1] - Jianye Real Estate (00832.HK) reports first-quarter sales of 12.836 billion yuan, up 69.8% year-on-year [1] - China Overseas Hongyang Group (00081.HK) sees a 3.38% increase in contract sales to 9.444 billion HKD for the first quarter [1] - Yincheng International Holdings (01902.HK) achieves total contract sales of 2.023 billion yuan in the first quarter [1] - Fantasia Holdings (01777.HK) reports March sales growth of 26.23% to 1.92 billion yuan [1] - Xinli International (00732.HK) sees a 12.5% increase in comprehensive operating net income to 4.072 billion HKD for the first quarter [1] - Hysun Engineering (02236.HK) reports new contract total value of 7.226 billion yuan for the first quarter, with uncompleted contract total value of 19.467 billion yuan [1] - Sunshine 100 China (02608.HK) achieves contract sales of 1.358 billion yuan in the first quarter [1] - Hengding Industrial (01393.HK) reports a decline of 18% in raw coal production to 458,000 tons for the first quarter [1] Mergers and Acquisitions - Rundong Auto (01365.HK) plans to sell a company operating 56 car dealerships for 3.4 billion yuan [1] - China Overseas Development (00688.HK) spends 7.726 billion yuan to acquire five land parcels in March [1] - Greenland Hong Kong (00337.HK) subsidiary sells 100% equity of a property development company, valued at no less than 2.8 billion yuan [1] - Longfor Green Group (00106.HK) plans to repurchase 49% equity of Suzhou Longhong Real Estate for 173 million yuan [1] Equity Financing - Vanke Enterprises (02202.HK) successfully issues approximately 263 million new H-shares, netting 7.78 billion HKD [2] - Ronshine China (03301.HK) plans to place up to 108 million shares to optimize shareholder structure [2] - Aoyuan Health (03662.HK) issues 26.25 million shares at a 19.56% discount due to the exercise of over-allotment rights [2] Major Events - Genscript (01548.HK) receives priority review designation from EMA for Janssen's JNJ-4528 drug [2] - Xun'an Technology (01647.HK) joint venture with Longma Bio obtains industrial hemp business qualification [2] - Haosha International (02200.HK) denies all allegations from Bonitas, claiming lack of professional understanding of its business model [2] - Kangzhe Pharmaceutical (00867.HK) extends exclusive promotion rights for New Vitality and Immodium until December 31, 2021 [2] - Weinan Group (01608.HK) secures its first distributed generation project in Sri Lanka [2] - Xinhua Pharmaceutical (00719.HK) completes transfer registration for proposed transfer, with Hualu Holdings becoming the direct controlling shareholder [2] - Zhejiang United Investment (08366.HK) plans to partner with Hengji to develop special equipment based on 5G network technology [2] - Tongfang Kontrol (01312.HK) sells 21% equity in Tongfang to China Nuclear Capital [2] - Alibaba Pictures (01060.HK) subsidiary signs a framework agreement for entertainment work cooperation with AGH [2] - Kingsoft (03888.HK) announces a framework agreement with Xiaomi to provide hardware products [2] - Binhai Services (03316.HK) partially exercises over-allotment rights as the price stabilization period ends [2]

Group 1 - Weisheng Holdings (03393) saw a nearly 6% increase in early trading, reaching HKD 24.48 with a transaction volume of HKD 35.6 million [1] - The company announced plans to spin off Weiyuan Energy for independent listing on the Hong Kong Stock Exchange, following the introduction of strategic investor Boyu Capital [1] - Boyu Capital will invest a total of RMB 380 million to subscribe for 48.81 million new shares of Weiyuan Energy, representing approximately 8% of its expanded share capital, with Weiyuan Energy valued at around RMB 4.75 billion [1] Group 2 - Guotou Securities (International) released a report anticipating collaboration between Weiyuan Energy and Boyu Capital, leveraging Boyu's extensive experience in data centers, technology, and new energy sectors to enhance business expansion and market competitiveness [1] - The strong demand for Weisheng Holdings' ADO business in data centers is entering a rapid growth phase, becoming a significant driver of overall business growth for the group [1]

Group 1 - The core viewpoint of the article is that Weisheng Holdings (03393) is experiencing a significant stock price increase following the announcement of the proposed spin-off of Weiyuan Energy for independent listing on the Hong Kong Stock Exchange [1] - Weiyuan Energy has introduced strategic investor Boyu Capital, which will invest a total of RMB 380 million to subscribe for 48.81 million new shares, representing approximately 8% of the enlarged share capital, with Weiyuan Energy's valuation estimated at around RMB 4.75 billion [1] - Guotai Junan Securities (International) anticipates that Weiyuan Energy will collaborate with Boyu Capital to leverage its extensive resources in data centers, technology, and new energy sectors, which is expected to enhance the company's business expansion and market competitiveness [1] Group 2 - Weisheng Holdings' ADO business is entering a rapid growth phase due to strong demand in data centers, becoming a significant driver of overall business growth for the group [1]

Core Viewpoint - JD Industrial's IPO marks the expansion of Liu Qiangdong's capital empire, with the company being the seventh listed entity in the JD ecosystem, which includes JD Group, JD Health, JD Logistics, Dada Group, and Debon Holdings [4][51]. Group 1: Company Overview - As of September 30, 2025, JD Industrial's revenue is still over 30% derived from JD Group and its affiliates, with net loans payable to JD Group amounting to 14.5 billion yuan, accounting for 35% of its total borrowings [3][50]. - JD Industrial was established in 2007 as part of JD Group's logistics expansion and became independent in 2018, focusing on modern logistics infrastructure operations [9][53]. - The company manages 285 modern infrastructure assets across 29 provinces in China and 10 overseas countries, with a total building area of 27.1 million square meters and an asset management scale of 121.5 billion yuan [9][54]. Group 2: Financial Performance - JD Industrial's revenue grew from 582 million yuan in 2020 to 3.417 billion yuan in 2024, with a year-on-year increase of 21.15% to 3.002 billion yuan in the first three quarters of 2025 [11][57]. - The company reported a cumulative loss of 3.188 billion yuan from 2023 to the first nine months of 2025, with adjusted net profits of 261 million yuan, 530 million yuan, and 823 million yuan for the respective periods [28][72]. - The average occupancy rate of JD Industrial's completed modern infrastructure assets exceeded 90%, significantly higher than the industry average [19][64]. Group 3: Market Position and Competition - JD Industrial ranks second in the Asia-Pacific region and third in China's new economy sector for modern infrastructure providers, despite holding only a 1.3% market share domestically [10][55]. - The company has faced a slowdown in expansion, with the number of modern infrastructure assets growing from 236 at the end of 2022 to 285 by September 2025 [14][60]. Group 4: Strategic Plans and Future Outlook - JD Industrial plans to accelerate its overseas expansion, with a significant portion of its IPO proceeds allocated to developing strategically important overseas infrastructure assets [18][62]. - The company aims to establish a global talent team to support its international operations, although it acknowledges the increased risks associated with overseas expansion [18][62]. - JD Industrial's future revenue from JD Group and its affiliates is expected to increase, with projected annual payment caps for infrastructure services reaching 2.5 billion yuan by 2028 [43][44].